KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Basic): 2009-2025

Historic EPS (Basic) for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $14.09.

  • Regeneron Pharmaceuticals' EPS (Basic) rose 13.63% to $14.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $43.45, marking a year-over-year increase of 0.49%. This contributed to the annual value of $40.90 for FY2024, which is 10.39% up from last year.
  • Regeneron Pharmaceuticals' EPS (Basic) amounted to $14.09 in Q3 2025, which was up 6.42% from $13.24 recorded in Q2 2025.
  • Regeneron Pharmaceuticals' EPS (Basic)'s 5-year high stood at $29.51 during Q2 2021, with a 5-year trough of $6.70 in Q1 2024.
  • Its 3-year average for EPS (Basic) is $10.26, with a median of $9.48 in 2023.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' EPS (Basic) spiked by 260.32% in 2021, and later slumped by 73.23% in 2022.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' EPS (Basic) stood at $20.98 in 2021, then crashed by 46.57% to $11.21 in 2022, then fell by 2.85% to $10.89 in 2023, then fell by 21.58% to $8.54 in 2024, then increased by 13.63% to $14.09 in 2025.
  • Its last three reported values are $14.09 in Q3 2025, $13.24 for Q2 2025, and $7.58 during Q1 2025.